A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing
A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing
In the register
The register attaches this trial to Dalosirvat (SM-04554) (Biosplice Therapeutics), currently at “Phase 2/3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Biosplice Therapeutics, Inc.
- Participants (registry)
- 49
- Start
- August 2015
- Primary completion
- April 2016
- Study completion
- April 2016
- Last registry update
- October 2026
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical SM04554 solution, Topical vehicle solution
Other trials of Dalosirvat (SM-04554)
A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.